Bovine mastitis is an inflammatory infection of the mammary gland in dairy cattle, which can be caused by bacteria, such as Staphylococcus aureus and Streptococcus agalactiae. The disease leads to economic losses for farmers from decreased milk production, discarded milk, increased treatment costs, and replacement costs. Early detection and treatment of mastitis is necessary to reduce its adverse effects on animal health and profitability of dairy farming. Various drugs like cephalosporins, corticosteroids, and aminoglycosides are used to treat bovine mastitis.
The global Bovine Mastitis Market is estimated to be valued at US$ 1497.52 Mn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increased antibiotic residues and bacterial resistance have resulted in regulations restricting antibiotic use in dairy farming. This has promoted research and development of non-antibiotic treatment options like mastitis vaccines, bacteriophages, plant extracts, and other therapies. Livestock-associated methicillin-resistant Staphylococcus aureus (MRSA) infections are also driving demand for alternatives to conventional antibiotics in bovine mastitis treatment. Advanced technologies like real-time sensors and genomic analysis are further aiding early detection and customized treatment of mastitis in dairy cattle.
Threat of new entrants: The threat of new entrants is moderate as the bovine mastitis market requires high R&D investments and strict regulatory approvals. Bargaining power of buyers: The bargaining power of buyers is high as the market has numerous established suppliers of bovine mastitis drugs and testing kits. Bargaining power of suppliers: The bargaining power of suppliers is moderate as suppliers have to comply with stringent regulatory norms for drug approvals and quality standards. Threat of new substitutes: The threat of new substitutes is low as there are limited treatment alternatives for bovine mastitis currently. Competitive rivalry: High due to presence of numerous national and multinational players competing on product development.
The Global Bovine Mastitis Market Size is expected to witness high growth, exhibiting CAGR of 5.2% over the forecast period, due to increasing dairy production and rising animal healthcare spending. Regionally, North America dominates the market currently owing to growing dairy farms and developed veterinary infrastructure. Europe is the second largest market driven by increasing livestock monitoring initiatives. Asia Pacific is expected to be the fastest growing region due to rising meat consumption and growing dairy industry.
Key players operating in the bovine mastitis market include Zoetis, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health, Norbrook, DeLaval, ImmuCell Corporation, Advanced Animal Diagnostics, and Nimrod Veterinary Products Ltd. Zoetis leads the market with wide portfolio of diagnostic kits and antimicrobial drugs for bovine mastitis treatment. Merck & Co focuses on R&D for novel therapeutics.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it